Patient response to enrollment regimen at LOT1. Response rates for patients receiving FCR, BR, or R monotherapy in LOT1 (based on all response assessments during LOT1). Bone marrow confirmation was not required for CR or PR assessment. NE, not evaluable; SD, stable disease.